Annual results show revenue shrinking while operating profit and net profit attributable to controlling shareholders swung sharply from year to year.
Revenue was KRW 544.6 billion in 2022, KRW 508.7 billion in 2023 (down 6.6%), KRW 458.3 billion in 2024 (down 9.9%) and KRW 450.3 billion in 2025 (down 1.7%), falling for three consecutive years from 2023 through 2025; 2022 was the largest year and 2025 the smallest.
Operating profit was KRW 23.5 billion in 2022, KRW 29.6 billion in 2023 (up 25.9%), KRW 10.5 billion in 2024 (down 64.5%) and KRW 23.6 billion in 2025 (up 124.6%); 2023 was the largest year and 2024 the smallest. The operating margin was 4.3% in 2022, 5.8% in 2023, 2.3% in 2024 and 5.2% in 2025, lowest in 2024.
Net profit attributable to controlling shareholders was KRW 28.1 billion in 2022, KRW 26.7 billion in 2023 (down 4.9%), KRW 75.8 billion in 2024 (up 183.6%) and KRW 12.9 billion in 2025 (down 82.9%), with 2024 the largest year.
In 2024 that figure far exceeded operating profit of KRW 10.5 billion, and total net profit including non-controlling interests was also KRW 75.8 billion; the non-operating items behind that gap need to be traced through the business report's income statement.
Operating cash flow was KRW 64 billion in 2022, KRW 51.2 billion in 2023, KRW 69.6 billion in 2024 and KRW 23.7 billion in 2025, a sharp drop in the latest year.
On a quarterly basis, operating profit of KRW 7.52 billion in the third quarter of 2025 fell 65.7% to KRW 2.58 billion in the fourth quarter, then recovered to KRW 6.23 billion in the first quarter of 2026 and KRW 7.99 billion in the second quarter before dropping to KRW 5.69 billion in the third quarter.
Revenue in the third quarter of 2026 was KRW 109.3 billion, down 5.4% year on year.
Net profit attributable to controlling shareholders was KRW 478 million in the fourth quarter of 2025, rose to KRW 6.76 billion in the second quarter of 2026 and was KRW 3.08 billion in the third quarter, totaling KRW 14.9 billion over the last four quarters.
The 2025 third-quarter cumulative remarks linked the injection segment's sales decline to weak domestic demand and lower shipping volumes.